Skip to content
10-Q

Quarterly Report

Quoin Pharmaceuticals, Ltd. QNRX

0001104659-25-107785

← back to feed
Filed
Nov 6, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$8.51M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$5.62M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $1.83M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $3.62M
Stockholders Equity Q3 2025 · Sep 30, 2025 −$1.21M
Stockholders Equity Q3 2025 · Jun 30, 2025 $2.55M
Stockholders Equity Q3 2025 · Mar 31, 2025 $5.93M
Stockholders Equity Q3 2025 · Dec 31, 2024 $9.2M
Stockholders Equity Q3 2025 · Sep 30, 2024 $5.44M
Stockholders Equity Q3 2025 · Jun 30, 2024 $7.48M
Stockholders Equity Q3 2025 · Mar 31, 2024 $9.13M
Stockholders Equity Q3 2025 · Dec 31, 2023 $5.66M
Current Liabilities Q3 2025 · Sep 30, 2025 $5.76M
Current Liabilities Q3 2025 · Dec 31, 2024 $4.18M
Total Liabilities Q3 2025 · Sep 30, 2025 $7.64M
Total Liabilities Q3 2025 · Dec 31, 2024 $6.5M
Current Assets Q3 2025 · Sep 30, 2025 $6.02M
Current Assets Q3 2025 · Dec 31, 2024 $14.93M
Total Assets Q3 2025 · Sep 30, 2025 $6.42M
Total Assets Q3 2025 · Dec 31, 2024 $15.71M
Sga Expense Q3 2025 · Sep 30, 2025 $1.74M
Sga Expense Q3 2025 · Sep 30, 2025 $5.06M
Sga Expense restated Q3 2025 · Sep 30, 2024 $1.45M
Sga Expense restated Q3 2025 · Sep 30, 2024 $4.57M
Rd Expense Q3 2025 · Sep 30, 2025 $2.28M
Rd Expense Q3 2025 · Sep 30, 2025 $6.71M
Rd Expense restated Q3 2025 · Sep 30, 2024 $1.08M
Rd Expense restated Q3 2025 · Sep 30, 2024 $2.55M
Net Income Q3 2025 · Sep 30, 2025 −$3.95M
Net Income Q3 2025 · Sep 30, 2025 −$11.46M
Net Income Q3 2025 · Jun 30, 2025 −$3.7M
Net Income Q3 2025 · Mar 31, 2025 −$3.81M
Net Income Q3 2025 · Sep 30, 2024 −$2.35M
Net Income Q3 2025 · Sep 30, 2024 −$6.65M
Net Income Q3 2025 · Jun 30, 2024 −$1.97M
Net Income Q3 2025 · Mar 31, 2024 −$2.33M